Side Effect Management | News

Brukinsa Shows Favorable Safety Profile Over Imbruvica in CLL

February 21st 2025

By Alex Biese

Researchers have found Brukinsa to be a potentially safer alternative for patients with chronic lymphocytic leukemia.

How Patients With Cancer Can Avoid Counterfeit Therapeutics Online

February 21st 2025

By Dr. Megan Menon

Dr. Megan Menon explains how patients can verify the authenticity of online prescription purchases for their cancer treatment.

What Patients With Cancer Need to Know About Counterfeit Drugs Risk

February 19th 2025

By Alex Biese

It’s a $4 billion a year industry that includes fraudulent anti-cancer drugs and opioid medications. Here is what patients need to know about the risk of counterfeit drugs.

An Expert Breaks Down the Effect of Diabetes on Urothelial Cancer Treatment

February 18th 2025

By Dr. Petros Grivas

Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.

Padcev May Be Safe in Older Patients With Bladder Cancer

February 14th 2025

By Darlene Dobkowski, MA

Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, a type of bladder cancer.

Facing Cancer Together: Jim and Melanie’s Patient-Caregiver Story

February 13th 2025

By Sue McCarthy

Diagnosed with stage 3B lung cancer in 2018, I joined a support group where I met Jim and Melanie, and learned about Jim's sarcoma diagnosis.

Breaking Down the FDA Labeling Update of Xeloda and 5-FU in Cancer Care

February 10th 2025

By Ryan Scott

The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine dehydrogenase deficiency.

An Expert Breaks Down What DPD Is and Labeling Updates From The FDA

February 10th 2025

By Dr. Gabriel A. Brooks

Dr. Gabriel A. Brooks discusses the recent FDA product labeling update for Xeloda and 5-FU which aims to highlight risks associated with DPD deficiency.

Tagrisso Associated With Cardiac Side Effects in Non-Small Cell Lung Cancer

February 7th 2025

By Spencer Feldman

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events and reduced overall survival.

Weight Gain Measurements May Be Underreported in ALK+ NSCLC Trials

February 4th 2025

By Spencer Feldman

Alecensa weight gain is underreported in ALK+ NSCLC trials, highlighting the need for increased awareness and proactive management of this side effect.